Tomivosertib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Tomivosertib
Accession Number
DB15219
Type
Small Molecule
Groups
Investigational
Description

Tomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).

Structure
Thumb
Synonyms
Not Available
External IDs
EFT508
Categories
Not Available
UNII
U2H19X4WBV
CAS number
1849590-01-7
Weight
Average: 340.387
Monoisotopic: 340.164773908
Chemical Formula
C17H20N6O2
InChI Key
HKTBYUWLRDZAJK-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)
IUPAC Name
6'-[(6-aminopyrimidin-4-yl)amino]-8'-methyl-2',5'-dihydro-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione
SMILES
CC1=C2N(C(=O)C(NC3=CC(N)=NC=N3)=C1)C1(CCCCC1)NC2=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
57617704
ChEMBL
CHEMBL4073443
PDBe Ligand
N45
PDB Entries
6ck6

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingTreatmentBreast Cancer1
1, 2TerminatedTreatmentMalignancies1
1, 2TerminatedTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentCastrate-resistant Prostate Cancer (CRPC)1
2Active Not RecruitingTreatmentTumors, Solid1
2CompletedTreatmentMicrosatellite Stable Relapsed or Refractory Colorectal Cancer1
2TerminatedTreatmentHepatocellular,Carcinoma / Triple Negative Breast Cancer (TNBC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.527 mg/mLALOGPS
logP0.53ALOGPS
logP0.82ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)10.84ChemAxon
pKa (Strongest Basic)6.35ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area113.24 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97.64 m3·mol-1ChemAxon
Polarizability35.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:01 / Updated on February 02, 2020 03:21